Disorder of eye
|
0.300 |
Biomarker
|
group |
GENOMICS_ENGLAND |
|
|
|
Disorder of eye
|
0.300 |
Biomarker
|
group |
GENOMICS_ENGLAND |
|
|
|
Disorder of eye
|
0.300 |
Biomarker
|
group |
GENOMICS_ENGLAND |
|
|
|
Eye Diseases, Hereditary
|
0.300 |
Biomarker
|
group |
CTD_human |
Diseases caused by defects in the visual cycle: retinoids as potential therapeutic agents.
|
16968212 |
2007 |
Retinal Dystrophies
|
0.110 |
Biomarker
|
group |
HPO |
|
|
|
Retinal Dystrophies
|
0.110 |
GeneticVariation
|
group |
BEFREE |
Because of the high density of Alu elements in RLBP1, a systematic search should be made for deletions in this gene when one or both alleles lack point mutations, in the case of RPA or flecked retinal dystrophy.
|
17065479 |
2006 |
Intellectual Disability
|
0.100 |
Biomarker
|
group |
HPO |
|
|
|
Retinal Diseases
|
0.030 |
GeneticVariation
|
group |
BEFREE |
The two RLBP1 genotypes presented a phenotypical and electrophysiological expression of progressive retinal disease similar to that previously described in homozygotes for the c.700C>T (p.R234W) RLBP1 mutation.
|
22551409 |
2013 |
Retinal Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
These additional mutations will aid ongoing functional studies and add to our understanding of the molecular pathology pertaining to RLBP1-associated retinopathies.
|
15234312 |
2004 |
Retinal Diseases
|
0.030 |
GeneticVariation
|
group |
BEFREE |
Mutations in the RLBP1 gene encoding the cellular retinaldehyde-binding protein (CRALBP) cause autosomal recessive progressive retinopathy, such as retinitis punctata albescens (RPA), Bothnia-type dystrophy (BD), Newfoundland rod-cone dystrophy (NFRCD), retinitis pigmentosa (RP) and fundus albipunctatus (FA).
|
25429852 |
2015 |
Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Biopsies of tumor and healthy tissues from 25 patients with OSCC were collected and subjected to RNA and protein extraction to confirm upregulation of RLBP1 in tumor tissues.
|
31336396 |
2019 |
Color vision defect
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Ophthalmoplegia
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Scotoma
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Photophobia
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Hyperreflexia
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Scotoma, Central
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Peripheral visual field loss
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Absent foveal reflex
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Atrophic macular change
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Blindness
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Electroretinogram abnormal
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Progressive visual loss
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Anteverted nostril
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Nasal bridge wide
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|